Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-day repeat dose pharmacodynamic study of SB-656933-AAA in ulcerative colitis
2007-005520-32Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elubrixin in autoimmune colitis, sponsored by GSK. Primary endpoints: Change in leukocyte SPECT scintigraphic activity scores at day 1 and day 7 and Safety and tolerability of 7-day repeat dosing. Started Aug 2008; status: terminated.
02
Drugs
elubrixin
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2007-005520-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005520-32.